Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy

Toshiaki Iwase, Evan N. Cohen, Hui Gao, Angela Alexander, Megumi Kai, Vivian Chiv, Xiaoping Wang, Savitri Krishnamurthy, Diane Liu, Yu Shen, Kumiko Kida, Alexandre Reuben, Rachel M. Layman, David L. Ramirez, Debasish Tripathy, Stacy L. Moulder, Clinton Yam, Vicente Valero, Bora Lim, James M. Reuben, Naoto T. Ueno

Open source

DOI: 10.1158/1078-0432.ccr-23-2947
Published: 2024-04-17
Container: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-23-2947,
  title = {Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy},
  author = {Toshiaki Iwase and Evan N. Cohen and Hui Gao and Angela Alexander and Megumi Kai and Vivian Chiv and Xiaoping Wang and Savitri Krishnamurthy and Diane Liu and Yu Shen and Kumiko Kida and Alexandre Reuben and Rachel M. Layman and David L. Ramirez and Debasish Tripathy and Stacy L. Moulder and Clinton Yam and Vicente Valero and Bora Lim and James M. Reuben and Naoto T. Ueno},
  year = {2024},
  journal = {Clinical Cancer Research},
  doi = {10.1158/1078-0432.ccr-23-2947},
  url = {https://doi.org/10.1158/1078-0432.ccr-23-2947}
}

RIS

TY  - JOUR
TI  - Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
AU  - Toshiaki Iwase
AU  - Evan N. Cohen
AU  - Hui Gao
AU  - Angela Alexander
AU  - Megumi Kai
AU  - Vivian Chiv
AU  - Xiaoping Wang
AU  - Savitri Krishnamurthy
AU  - Diane Liu
AU  - Yu Shen
AU  - Kumiko Kida
AU  - Alexandre Reuben
AU  - Rachel M. Layman
AU  - David L. Ramirez
AU  - Debasish Tripathy
AU  - Stacy L. Moulder
AU  - Clinton Yam
AU  - Vicente Valero
AU  - Bora Lim
AU  - James M. Reuben
AU  - Naoto T. Ueno
PY  - 2024
JO  - Clinical Cancer Research
DO  - 10.1158/1078-0432.ccr-23-2947
UR  - https://doi.org/10.1158/1078-0432.ccr-23-2947
ER  -

APA

Iwase, T., Cohen, E. N., Gao, H., Alexander, A., Kai, M., Chiv, V., Wang, X., Krishnamurthy, S., Liu, D., Shen, Y., Kida, K., Reuben, A., Layman, R. M., Ramirez, D. L., Tripathy, D., Moulder, S. L., Yam, C., Valero, V., Lim, B., Reuben, J. M., & Ueno, N. T. (2024). Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-23-2947

Source records

crossref · retrieved 2026-09-27T03:48:33.467Z